Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 3, 2016, Pages 539-546

  Parfrey, Patrick S ^a   Block, Geoffrey A ^b   Correa Rotter, Ricardo ^c   Drueke, Tilman B ^d   Floege, Jurgen ^e   Herzog, Charles A ^f   London, Gerard M ^g   Mahaffey, Kenneth W ^h   Moe, Sharon M ⁱ   Wheeler, David C ^j   Chertow, Glenn M ^h  

^a Health Sciences Centre St John's   (Canada)

^b Denver Nephrology   (United States)

^c National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY OF MINNESOTA   (United States)

^g Medicine Department   (France)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CINACALCET; FIBROBLAST GROWTH FACTOR 23; CALCIMIMETIC AGENT;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; DATA BASE; HEART FAILURE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PLANNING; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; SECONDARY HYPERPARATHYROIDISM; SELECTION BIAS; SENSITIVITY ANALYSIS; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERPARATHYROIDISM, SECONDARY; METHODOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TREATMENT OUTCOME;

CALCIMIMETIC AGENTS; CARDIOVASCULAR DISEASES; CINACALCET HYDROCHLORIDE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84960085908     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06370615     Document Type: Article

References (33)

1. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482-2494, 2012
2. Parfrey PS, Barrett BJ: Cardiovascular disease and chronic kidney disease. In: Chronic Kidney Disease, edited by Kimmel PL, Rosenberg ME, Waltham MA, Academic Press, 2015, pp 181-198
3. McCullough PA, Agrawal V, Danielewicz E, Abela GS: Accelerated atherosclerotic calcification and Monckeberg’s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 3: 1585-1598, 2008
4. Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drueke TB, Floege J, Kudo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman M-L, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower Cardio-Vascular Events (EVOLVE) Trial Investigators: Effects of cinacalcet on atherosclerotic and non atherosclerotic cardiovascular events in patients receiving hemodialysis. The Evaluation of Cinacalcet HCC Therapy to lower CardioVascular Events (EVOLVE) Trial. J Am Heart Assoc 17: e001363, 2014
5. Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 3: 1599-1605, 2008
6. Seltzer JH, Turner JR, Geiger MJ, Rosano G, Mahaffey KW, White WB, Sabol MB, Stockbridge N, Sager PT: Centralized adjudication of cardiovascular end points in cardiovascular and non-cardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. Am Heart J 169: 197-204, 2015
7. Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA, Ronco C; ADQI XI Workgroup: Proposal for a functional classification system of heart failure in patients with end-stage renal disease: Proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. J Am Coll Cardiol 63: 1246-1252, 2014
8. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995
9. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Williamson JD, Leenan FHH, Einhorn PT, Randall OS, Golden JS, Haywood LJ, and the ALLHAT Collaborative Research Group: Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack Trial (ALL HAT) participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 3: 10, 2002
10. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA: Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 143: 242-248, 2002
11. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM; For the PURSUIT Investigators: Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: Review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2: 187-194, 2001
12. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG: The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 98: 4834-4844, 2013
13. Chu R, Walter SD, Guyatt GP, Devereaux PJ, Walsh M, Thorlund K, Thabane L: Assessment and implication of prognostic balance in randomized controlled trials with a binary outcome-a simulation study. PLOS One 7: e36677, 2012
14. Baigent C, Landrey M, Emberson J, Wheeler DC, Tomson C; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimide in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo controlled trial. Lancet 377: 2182-2192, 2011
15. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
16. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials): The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134: 663-694, 2001
17. Austin PC, Manca A, Zwarenstein M, Juurlink DN, Stanbrook MB: A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: A review of trials published in leading medical journals. J Clin Epidemiol 63: 142-153, 2010
18. Hernández AV, Eijkemans MJ, Steyerberg EW: Randomized controlled trials with time-to-event outcomes: How much does prespecified covariate adjustment increase power? Ann Epidemiol 16: 41-48, 2006
19. Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: The effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cina-calcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 10: 791-799, 2015
20. Walach H, Sadaghiani C, Dehm C, Bierman D: The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials-a secondary analysis. BMC Med Res Methodol 5: 26, 2005
21. Tripepi G, Heinze G, Jager KJ, Stel VS, Dekker FW, Zoccali C: Lag-censoring analysis: Lights and shades. Nephrol Dial Trans-plant 30: 700-705, 2015
22. Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM: Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. Pharm Stat 14: 242-251, 2015
23. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz D, Diaz-Granados N, Vandvik PO, Malaga G, Srinathan SK, Dahm P, Johnston BC, Alonso-Coello P, Hassouneh B, Walter SD, Heels-Ansdell D, Bhatnagar N, Altman DG, Guyatt GH: Credibility of claims of subgroup effects in randomized controlled trials: systematic review. BMJ 344: e1553, 2012
24. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial. Clin J Am Soc Nephol 10: 800-807, 2015
25. Ketteler M, Biggar PH: Evolving calciphylaxis-what randomized, controlled trials can contribute to the capture of rare diseases. Clin J Am Soc Nephrol 10: 726-728, 2015
26. Hsu CY, Ballard S, Batlle D, Bonventre JV, Bottinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG; CKD Biomarkers Con-sortium: Cross-disciplinary biomarkers research: lessons learned by the CKD Biomarkers Consortium. Clin J Am Soc Nephrol 10: 894-902, 2015
27. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
28. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
29. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation 132: 27-39, 2015
30. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol 26: 1466-1475, 2015
31. Bover J, Urena P, Ruiz-García C, daSilva I, Lescano P, Del Carpio J, Ballarín J, Cozzolino M: Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroid-ism [published online ahead of print July 29, 2015]. Clin J Am Soc Nephrol doi: 10.2215/CJN.01760215
32. Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH: Economic evaluation of cinacalcet in the United States: The EVOLVE trial [published online ahead of print October 5, 2015]. Value Health doi: 10.1016/j.jval.2015.08.007
33. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007